Intranasal ketorolac, brand name known as “Sprix” was found to be superior to placebo and non inferior, or no worse than intranasal sumatriptan for the acute abortive treatment of moderate to severe migraine, according to data published in the February issue of Headache. Intranasal ketorolac may be appropriate for patients whose nausea makes the use of oral medications difficult, and the formulation also offers an effective alternative for patients who cannot or do not want to use a triptan nasal spray, according to the authors.

Research suggests that parenteral ketorolac may be as effective as or more effective than certain triptans and other acute abortive therapies. No previous study, however, had directly compared intranasal ketorolac with any migraine-specific therapy.

Dr. Robbins added that this medication is very expensive, and can only be found in specialty pharmacies.

neurologyreviews.com

April 2016

 

Pin It on Pinterest